Why We’re Falling Behind On Brain Innovation

TIME

Brain science is taking a hit, according to a recent series of papers published in a special issue of the Cell Press journal Neuron.

“While the disease burden and economic impacts are on the rise, progress in the development of new therapeutics and treatment approaches has appeared to have stalled,” reads an editorial introducing the issue. “Approval for new therapeutics (whether drugs, devices, or other treatment approaches) for nervous system disorders have been declining and most of the treatments we currently have are not disease modifying.”

Large pharmaceutical companies like GlaxoSmithKline, AstraZeneca, Merck, Pfizer and Sanofi-Aventis have closed or downsized their brain research divisions, according to one paper, a move the study authors believe reflects a growing view that developing drugs for the brain is too difficult and time-consuming. In another report, researchers argue that there are not enough opportunities for various stakeholders to meet and collaborate…

View original post 384 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s